Pientzehuang invests 200m yuan in healthcare fund, announces executive changes

Zhangzhou Pientzehuang Pharmaceutical Co. Ltd. is investing 200,000,000 yuan as a limited partner in the CICC (Zhangzhou) Medical Industry Investment Partnership (Limited Partnership), representing 20% of the target fundraising size of 1,000,000,000 yuan. This investment, aimed at the medical and health industry, constitutes a related party transaction as other limited partners are subsidiaries of the controlling shareholder, Zhangzhou Jiulongjiang Group Co. Ltd. The investment has been approved by the board of directors and the supervisory board.

Separately, Yang Haipeng has resigned from his roles as director and chief accountant due to work adjustments, effective September 28, 2025. He will continue as an advisor to the company. The board's audit committee has appointed vice general manager He Wei to temporarily assume the duties of chief accountant.

The CICC Healthcare Fund is currently in the preparatory stage, with formal partnership agreements and regulatory registrations still pending. This investment is not expected to significantly impact the company's financial performance or operating results for the current year.